Rituxan Hycela Injection, Solution
Product Images NDC 50242-108

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Rituxan Hycela (NDC 50242-108). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (11.7 mL Vial Carton)

Rituxan Hycela is a medication that is administered via subcutaneous injection over 5 to 7 minutes, using a single-dose vial. It contains both rituximab and hyaluronidase human, with a strength of 1,400 mg and 23,400 Units/11.7 mL (120mg and 2,000 Units/mL). This medication is intended for subcutaneous use only and any unused portion should be discarded. Pharmacies should dispense the accompanying medication guide to patients who are prescribed this medication.*

FDA Label Image

Principal Display Panel (13.4 mL Vial Carton)

Rituxan Hycela is a medication that contains rituximab and hyaluronidase human, used for subcutaneous injection only. It comes in a single-dose vial containing 1,600 mg and 26,800 Units/13.4 mL (120 mg and 2,000 Units/mL). It should be administered over 5 to 7 minutes, and any unused portion should be discarded. Pharmacists are advised to dispense the accompanying Medication Guide to each patient. Manufactured by Genentech | ®Biogene. NDC 50242-109-0.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.